Letters Idiopathic pulmonary fibrosis

Underestimating treatment benefit of lung transplantation for idiopathic pulmonary fibrosis

BMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g24 (Published 06 January 2014) Cite this as: BMJ 2014;348:g24

This article has a correction. Please see:

  1. P Riddell, respiratory registrar1,
  2. D Eaton, consultant in lung transplant surgery1,
  3. A B Miller, professor of respiratory medicine2,
  4. A U Wells, professor of respiratory medicine3,
  5. J J Egan, professor of respiratory/transplant medicine1
  1. 1Advanced Lung Disease and Transplant Programme, Mater Misericordiae University Hospital, Dublin, Republic of Ireland
  2. 2Academic Respiratory Unit, School of Clinical Sciences, Bristol University, Bristol, UK
  3. 3Interstitial Lung Disease Unit, Royal Brompton Hospital and National Heart and Lung Institute, London, UK
  1. priddell{at}mater.ie

Dempsey and Miller drew attention to the inadequacy of medical treatments for idiopathic pulmonary fibrosis (IPF) and the optimism provided by the emergence of pirfenidone.1However, only a cursory note was given to lung transplantation, which seems to have been dismissed by the authors, who describe patients as “too frail or old” with “serious …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe